Quinn Opportunity Partners’s Structure Therapeutics GPCR Stock Holding History

Quinn Opportunity Partners’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$482K	Sell	10,000 -15,000	-60%	-$1.03M	0.03%	273
2025 Q4	$1.74M	Sell	25,000 -17,000	-40%	-$694K	0.07%	187
2025 Q3	$1.18M	Hold	42,000	–	–	0.08%	174
2025 Q2	$871K	Buy	42,000 +20,000	+91%	+$440K	0.07%	198
2025 Q1	$381K	Buy	22,000 +10,000	+83%	+$245K	0.03%	294
2024 Q4	$325K	Hold	12,000	–	–	0.02%	298
2024 Q3	$527K	Hold	12,000	–	–	0.05%	190
2024 Q2	$471K	Buy	+12,000	New	+$493K	0.05%	181

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Quinn Opportunity Partners's GPCR Position: Q1 2026 in Review

Quinn Opportunity Partners reduced its Structure Therapeutics (GPCR) stake by 60% in Q1 2026, selling an estimated $1.03M and leaving 10,000 shares worth $482K. The position accounts for 0.03% of the portfolio, ranked #273.

Quinn Opportunity Partners first reported a position in GPCR in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.74M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Quinn Opportunity Partners held 10,000 shares of Structure Therapeutics worth $482K as of Q1 2026.
Quinn Opportunity Partners sold 15,000 Structure Therapeutics shares in Q1 2026, an estimated $1.03M.
Structure Therapeutics made up 0.03% of Quinn Opportunity Partners's portfolio in Q1 2026, its #273 holding.
Quinn Opportunity Partners first reported a position in Structure Therapeutics in Q2 2024 and has held it in 8 quarters since.
Quinn Opportunity Partners's Structure Therapeutics position peaked at $1.74M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Quinn Opportunity Partners's 13F filing for Q1 2026, filed 15 May 2026.